301207.SZ
301207.SZ
CNE1000058J9
HUALAN VAC
Loading chart...

Company Profile

Hualan Biological Vaccine Inc. engages in the research and development, production, and sale of vaccines and genetically engineered biological products in China. The company's main products include influenza virus split vaccine, quadrivalent influenza virus split vaccine, quadrivalent influenza virus split vaccine (pediatric formulation), H1N1 influenza A virus split vaccine, ACYW135 group meningococcal polysaccharide vaccine, recombinant hepatitis B vaccine (Hansenula polymorpha), group A and C meningococcal polysaccharide vaccine, freeze-dried human rabies vaccine (Vero cells), and adsorbed tetanus vaccine. It also offers products under development, such as freeze-dried Group A and Group C meningococcal conjugate vaccine, adsorbed cell-free tridiphtheria-tetanus combined vaccine, freeze-dried Haemophilus influenzae type b conjugate vaccine, and recombinant zoster vaccine (CHO cells), mRNA influenza vaccines, adsorbed tetanus vaccine, and novel adjuvanted influenza vaccines. In addition, it sells self-produced products. The company was founded in 2005 and is based in Xinxiang, China.

Related stocks

688062.SS
688062.SS • China
MABWELL (SHANGHAI) BIOSCIENCE C
24.78 CNY
1.66B USD 1Y -47.7%
9606.HK
9606.HK • China
DUALITYBIO-B
182.7 HKD
2.13B USD 1Y -42.1%
300204.SZ
300204.SZ • China
STAIDSON BIO
20.66 CNY
1.67B USD 1Y -38.7%
600201.SS
600201.SS • China
JINYU BIO-TECHNOLOGY CO LTD
11.84 CNY
1.95B USD 1Y +21.7%
688105.SS
688105.SS • China
NANJING VAZYME BIOTECH CO LTD
26.6 CNY
2.06B USD 1Y +49.7%
2595.HK
2595.HK • China
GENFLEET-B
28.6 HKD
1.4B USD 1Y -21%
1952.HK
1952.HK • China
EVEREST MED
29.6 HKD
1.33B USD 1Y -47.1%
1877.HK
1877.HK • China
JUNSHI BIO
17.65 HKD
2.31B USD 1Y -40.6%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
48.5% p.a.
Max Drawdown (5Y)
-68.0%
Sharpe Ratio (5Y)
-0.40
Beta Factor
0.58
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 58.5 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (48.5% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -68.0% in the extended horizon.
ende